Research Insights

The 3D printing industry has come a long way over the last many years; the technology has the potential of revolutionising the way things occur currently. Many industries have already benefitted from multiple advancements in this field, resulting in improved and more efficient processes worldwide. A quick look at www.3dprintingchannel.com suggests that 3D printing has multi-faceted dimensions; the technology has recently been used in varied industries such as automotive, medical, business, indus

The concept of Antibody drug conjugates (ADCs) is simple - a cytotoxic / chemotherapy drug is delivered to the target tissue through linking it with a monoclonal antibody. However, the practical challenge of manufacturing such complex and highly toxic molecules is huge. The multi-component aspect of ADCs deems it necessary to have both biologic and high-potency facilities. Despite the fact that this new class of therapeutic agents is gaining increased attention from both small and large pharm

The injectable drug delivery market holds significant potential for the future. From the conventional syringes with vials and painful needles to the modern-day pre-filled syringes, pen-injectors, needle free injectors and auto-injectors, the injectable drug delivery devices market has come a long way. Taking the concept of self-injectors to a new stratum, ‘Bolus Injectors’ have surfaced recently. Also known as non-insulin patch pumps, these devices not only offer a range of benefits

Antibody based therapeutics are the fastest growing segment of the drugs and biologics market. There are 30 approved antibody based therapeutics available in the US and European markets since the launch of first anti-CD3 antibody, Orthoclone Okt3, in 1986. A bispecific antibody is a second generation immunotherapy, an upgraded version of monoclonal antibody improved in structure and functionality. The conjugated artificial antibodies are formed by physically putting together two monoclonal an

Engineered antibodies are antibody based therapeutics, which are gaining increasing attention from both large and small pharmaceutical companies. Developed through introduction of modifications in monoclonal antibodies, the aim is to develop antibodies with improved efficacy. Research done in the last decade to develop engineered antibodies has yielded a rich knowledge base on how to develop and market these next generation antibodies. These therapeutic antibodies seem to be more promising, w

Antibody Drug Conjugates (ADC) are a new class of biologic therapeutics. These are complex molecules comprising of an antibody linked to few cytotoxin molecules through linker technology. This class of biologics is attracting the attention of drug developers, with several large and small companies entering the market through collaboration and licensing agreements with technology providers. The ADC market is still in its infancy. So far, three ADCs have received market approval. However, the f

Prefilled syringes are gaining strong acceptance in the market as drug delivery systems for injectable drugs. They have become a preferred device for parenteral administration of drugs, mainly used for treatment of chronic conditions requiring patients to self-administer medication several times a week. The rising demand for prefilled syringes is driving the manufacturers to introduce improvements in technology related to the material of prefilled syringes, and lubrication technology to reduc

Targeted therapeutics and companion diagnostics are the pillars of personalised medicine. Personalised medicine is a genome-based therapeutic approach that aims to adopt customised treatment for each individual. It uses aspects of genetic testing for checking potential abnormalities and tailoring the treatment so as to make it as individualised as the disease itself. Targeted drugs have been fast to overshadow the traditional drugs, which favour the concept of one-size-fits-all. This has prim

Alzheimer’s disease is a neurodegenerative disease of the brain which leads to loss of memory and cognitive functions. With ageing world population, the number of patients suffering from Alzheimer’s disease is expected to increase in the future. There is a huge unmet need in the market owing to lack of effective, disease-modifying drugs. Alzheimer’s treatment is a high risk, high reward market. Drugs currently available in the market have reached maturity; patents of leading

Neurostimulation devices are gaining acceptance as therapy alternative for certain chronic conditions such as pain. These devices have also found use in management of movement disorders including Parkinson’s disease and epilepsy. The currently available neurostimulators mainly focus on spinal cord stimulation (SCS), deep brain stimulation (DBS), vagus nerve stimulation (VNS) and sacral nerve stimulation (SNS). The market is still niche, with limited number of devices available in the ma